Multidrug-resistant tuberculous meningitis: Clinical problems and concentrations of second-line antituberculous medications

Annals of Pharmacotherapy

Volumn 33, Issue 11, 1999, Pages 1184-1188

  DeVincenzo, John P ^a,b   Berning, Shaun E ^c   Peloquin, Charles A ^e   Husson, Robert N ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NONE

Author keywords

Cycloserine; Ethionamide; Meningitis; Tuberculosis

Indexed keywords

CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; RIFABUTIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CASE REPORT; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; TUBERCULOUS MENINGITIS; ANTIBIOTIC RESISTANCE; BLOOD; CEREBROSPINAL FLUID; DRUG EFFECT; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; INFANT; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MENINGEAL;

EID: 0032589942     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19008     Document Type: Article

References (32)

1. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998;338:1641-9.
2. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
3. Kilpatrick ME, Girgis NI, Yassin MW, Abu El Ella AA. Tuberculous meningitis - clinical and laboratory review of 100 patients. J Hyg 1986; 96:231-8.
4. Visudhiphan P, Chiemchanya S. Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. J Pediatr 1989;114:875-9.
5. Sumaya CV, Simek M, Smith MH, Seidemann MF, Ferriss GS, Rubin W. Tuberculous meningitis in children during the isoniazid era. J Pediatr 1975;87:43-9.
6. Jacobs RF, Sunakorn P, Chotpitayasunonah T, Pope S, Kelleher K. Intensive short course chemotherapy for tuberculous meningitis. Pediatr Infect Dis J 1992;11:194-8.
7. Waecker NJ, Connor JD. Central nervous system tuberculosis in children: a review of 30 cases. Pediatr Infect Dis J 1990;9:536-43.
8. Peloquin CA. Antituberculosis drugs: pharmacokinetics. In: Heifets LB, ed Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:59-65.
9. Berenguer J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med 1992;326:668-72.
10. Horn DL, Hewlett D, Peterson S, Sabido D, Opal SM. RISE-resistant tuberculous meningitis in AIDS patient. Lancet 1993;341:177-8.
11. Centers for Disease Control. Multi-drug resistant tuberculosis - North Carolina. MMWR Morbid Mortal Wkly Rep 1987;35(51-52):785-7.
12. Watt G, Selkon JB, Bautista S, Laughlin LW. Drug resistant tuberculous meningitis in the Philippines: report of a case. Tubercle 1989;70:139-41.
13. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993;77:1253-62.
14. Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Morbid Mortal Wkly Rep 1992;41(RR-11):61-71.
15. Hobby GL, Johnson PM, Crawford-Gagliardi L, Greetham L, Lenert TF. Primary drug resistance: a continuing study of tubercle bacilli in a veteran population within the United States. IV. Factors influencing the observed frequency of resistance. Am Rev Respir Dis 1965;91:575-82.
16. Donald PR, Malan C. Cerebrospinal fluid lactate and lactate dehydrogenase activity in the rapid diagnosis of bacterial meningitis. S Aft Med J 1986;69:39-42.
17. Carlini SM, Beyers N, Schoeman JF, Nel ED, Truter EJ, Donald PR. Adenylate kinase activity in the cerebrospinal fluid of children with tuberculous meningitis and its relationship to neurological outcome. Scand J Infect Dis 1997;29:275-80.
18. Coovadia YM, Dawood A, Ellis ME, Coovadia HM, Daniel TM. Evaluation of adenosine deaminase activity and antibody to Mycobacterium tuberculosis antigen 5 in cerebrospinal fluid and the radioactive bromide partition test for the early diagnosis of tuberculosis meningitis. Arch Dis Child 1986;61:428-35.
19. Ribera E, Martinez Vazquez JM, Ocana I, Segura RM, Pascual C. Activity of adenosine deaminase in cerebrospinal fluid for the diagnosis and follow-up of tuberculous meningitis in adults. J Infect Dis 1987;155:603-7.
20. Nozaki H, Fukuuchi Y, Koto A, Tanaka K, Kobari M. Time-course of adenosine deaminase activity in the cerebrospinal fluid in patients with tuberculous meningitis (Japanese). Kekkaku 1994;69:663-70.
21. Shankar P, Manjunath N, Mohan KK, Prasad K, Behari M, Shriniwas, et al. Rapid diagnosis of tuberculous meningitis by polymerase chain reaction. Lancet 1991;337:5-7.
22. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-3.
23. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston JM, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50.
24. Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW, et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. Ann Intern Med 1992;117:191-6.
25. Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis 1993;148:650-5.
26. Peloquin CA, Henshaw TL, Huitt GA, Berning SE, Nitta AT, James GT. Pharmacokinetic evaluation of p-aminosalicylic acid granules. Pharmacotherapy 1994;14:40-6.
27. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999;43:568-72.
28. Narang PK, Lewis RC, Bianchine JR. Rifabutin absorption in humans: relative bioavailability of food effect. Clin Pharmacol Ther 1992;52:335-41.
29. McEvoy GK, ed. AHFS drug information 1999. Bethesda, MD: American Society of Health-Systems Pharmacists, 1999.
30. American Academy of Pediatrics Report of the Committee on Infectious Diseases. Tuberculosis. In: Peter G, ed. 1997 Red book. Elk Grove Village, IL: American Academy of Pediatrics, 1997:494-5.
31. Donald PR, Seifart HI. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J Pediatr 1989;115:483-6.
32. Heifets LB. Antituberculosis drugs: antimicrobial activity in vitro. In: Heifets LB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:13-58.